Health
Experimental Alzheimer’s Drug Shows Promise in Reducing Dementia Risk
A new experimental treatment targeting amyloid plaques in the brain has shown promising early results in reducing the risk of Alzheimer’s-related dementia among asymptomatic patients. The drug, gantenerumab, was studied in a small group of individuals genetically predisposed to the neurodegenerative disease.
Researchers tracked 22 patients with genetic mutations that cause an overproduction of amyloid, a protein that clumps together to form plaques in the brain, a hallmark of Alzheimer’s disease. According to findings published in Lancet Neurology, participants who took gantenerumab for eight years saw their risk of developing symptoms drop from 100% to approximately 50%.
Long-Term Treatment May Be Key
The study’s lead author, Randall Bateman, a professor of neurology at Washington University School of Medicine in the U.S., emphasized the significance of the results. “Everyone in this study was destined to develop Alzheimer’s disease, and some of them haven’t yet,” Bateman said. “To give them the best opportunity to stay cognitively normal, we have continued treatment with another anti-amyloid antibody in hopes they will never develop symptoms at all.”
Notably, cognitive benefits were observed only in patients who received the treatment for the full eight years. Those who were treated for only two to three years did not show noticeable improvements, suggesting that long-term preventive therapy may be necessary for effectiveness.
Challenges and Limitations
Despite the encouraging results, experts have pointed out limitations in the study. Charles Marshall, a professor of clinical neurology at Queen Mary University of London, called the findings “very exciting” but noted that the study involved a small number of participants and was a secondary evaluation rather than a primary clinical trial.
Another concern is that gantenerumab is not as effective as some newer amyloid-reducing treatments, suggesting there may be even better options available. The drug was discontinued in 2022 after failing to slow symptoms in a trial involving over 1,900 participants with more common forms of Alzheimer’s disease.
Future Research Needed
While gantenerumab has shown potential in genetically predisposed individuals, further research is required to determine the optimal treatment duration, the effects on non-genetic cases of Alzheimer’s, and possible side effects. Some anti-amyloid drugs have been linked to brain abnormalities and localized swelling, though most side effects resolve on their own. In the study, two participants had to stop taking the drug due to side effects, but no life-threatening adverse effects were reported.
The findings contribute to the growing body of research on anti-amyloid therapies, highlighting the need for continued investigation into more effective Alzheimer’s prevention and treatment strategies.
Health
Europe Faces Growing Challenges in Meeting Medical Care Needs, EU Report Shows

A new report has highlighted stark disparities in healthcare access across Europe, revealing that a growing number of citizens face unmet medical needs due to systemic issues such as high costs and long waiting times.
According to the latest data from Eurostat and the Health at a Glance: Europe 2024 report, 3.8 per cent of EU residents aged 16 and over reported unmet medical needs in the past year. However, the percentage climbs significantly when focusing solely on individuals who actively required healthcare services — with some countries reporting unmet needs among over 20 per cent of this group.
The causes are twofold: healthcare system barriers, including long waiting lists and treatment costs, account for 2.4 per cent of all cases, while 1.4 per cent stem from personal reasons such as fear of doctors, lack of time, or lack of knowledge about available care.
Unmet healthcare needs vary widely across the continent. Estonia tops the list within the EU, with 15.5 per cent of people reporting unmet needs, followed closely by Greece and Albania, each over 13 per cent. Even wealthier Nordic countries show surprising figures — Denmark (12.2 per cent), Finland, and Norway (over 7.5 per cent) — despite high healthcare spending. Conversely, countries such as Germany (0.5 per cent), Austria (1.3 per cent), and the Netherlands (1.4 per cent) report the lowest levels, pointing to more efficient and accessible healthcare systems.
Cost is a dominant barrier in nations like Greece and Albania, where over 9 per cent of citizens cited unaffordable care. In contrast, long waiting times are the primary issue in countries like Estonia (12 per cent) and Finland (7.5 per cent).
Income inequality also plays a major role. On average, 3.8 per cent of low-income individuals across the EU report unmet needs due to healthcare system issues — more than triple the 1.2 per cent reported by higher-income groups. In Greece, that gap is particularly wide, with 23 per cent of low-income respondents affected.
Healthcare experts say these disparities reflect more than just economic factors. Dr. Tit Albreht, President of the European Public Health Association (EUPHA), noted, “Unmet health needs arise from different reasons, including how well healthcare governance integrates services to meet population needs.”
Industry leaders, such as Tina Taube of the European Federation of Pharmaceutical Industries and Associations (EFPIA), stressed the importance of timely access to diagnosis and treatment. “Unmet needs are context-specific,” she said. “It’s not just about product availability, but also healthcare system readiness.”
Andy Powrie-Smith of EFPIA added that patients in some European countries wait up to seven times longer than others for the same treatments due to regulatory delays and varying national infrastructures.
The findings underscore the need for a more coordinated, equitable healthcare strategy across the continent, especially as Europe faces the challenges of an ageing population and increasingly complex medical technologies.
Health
Chinese Nationals Charged in U.S. with Smuggling Toxic Fungus Labeled a Potential Agroterrorism Threat

U.S. federal authorities have charged two Chinese nationals in connection with smuggling a dangerous agricultural fungus into the country, a move investigators describe as posing significant national security risks.
Yunqing Jian, 33, and Zunyong Liu, 34, are accused of conspiracy, smuggling, making false statements, and visa fraud after allegedly attempting to bring Fusarium graminearum — a toxic fungus capable of devastating crops and harming humans and livestock — into the United States. The case was detailed in a court filing by the Federal Bureau of Investigation (FBI) in Detroit.
The fungus, which targets essential food staples like wheat, maize, barley, and rice, is described in a scientific journal cited by the FBI as a “potential agroterrorism weapon.” Experts warn that its spread could inflict serious damage on global food security and agricultural economies.
U.S. Attorney Jerome Gorgon Jr. emphasized the seriousness of the case, stating: “The alleged actions of these Chinese nationals, including a loyal member of the Chinese Communist Party, are of the gravest national security concerns.”
Jian made her first appearance in a Detroit federal court on Tuesday and remains in custody awaiting a bond hearing scheduled for Thursday. A court-appointed attorney for her initial appearance declined to comment.
According to the FBI’s complaint, the investigation began in July 2024 when Liu was stopped at Detroit Metropolitan Airport. During a routine screening, customs officials discovered suspicious red plant material in his backpack. Liu initially claimed not to know what it was but later admitted he planned to use it for research purposes at the University of Michigan, where Jian is currently employed and where Liu previously worked.
Authorities say Liu’s mobile phone contained an article titled “Plant-Pathogen Warfare under Changing Climate Conditions,” raising further concerns about the intended use of the samples. The FBI believes the two individuals were coordinating to introduce the pathogen into a U.S. research setting without proper clearance or oversight.
Liu was denied entry to the U.S. and deported in July. Charges against both individuals were filed this week, as prosecutors continue to investigate the scope of the alleged conspiracy.
The case underscores growing concerns in the U.S. over biosecurity and potential misuse of scientific research amid rising geopolitical tensions.
Health
US Expands Measles Vaccination Guidance Amid Global Surge in Cases
-
Business1 year ago
Saudi Arabia’s Model for Sustainable Aviation Practices
-
Business1 year ago
Recent Developments in Small Business Taxes
-
Politics1 year ago
Who was Ebrahim Raisi and his status in Iranian Politics?
-
Business11 months ago
Carrectly: Revolutionizing Car Care in Chicago
-
Business11 months ago
Saudi Arabia: Foreign Direct Investment Rises by 5.6% in Q1
-
Technology1 year ago
Comparing Apple Vision Pro and Meta Quest 3
-
Politics1 year ago
Indonesia and Malaysia Call for Israel’s Compliance with ICJ Ruling on Gaza Offensive
-
Sports10 months ago
Keely Hodgkinson Wins Britain’s First Athletics Gold at Paris Olympics in 800m